Moffitt Cancer Center Partners with PathAI to Advance Digital Pathology and AI in Cancer Care

Moffitt and PathAI’s Partnership to Initiate Digitalization

Announcement

PathAI, a known leader in digital pathology solutions and artificial intelligence, entered a multi-year partnership with Moffitt Cancer Center, one of the popular cancer hospitals and a global leader in cancer research. The collaboration intends to deploy PathAI’s digital pathology platform, AISight Dx, throughout Moffitt’s pathology programs to transition innovation and cancer identification.

Digitization

The AISight Dx is one of PathAI’s cloud-familiar digital pathology image management systems, introduced to contribute to translational research and laboratory workflow use cases. It merges viewing, enterprise-scale slide management, and involvement with easy AI integration, improvement in accuracy and speed, and fueling scalable pathology operational efficiencies. The collaboration also develops data for the collation of real-world multimodal data, joint research programs, co-development of future AI-powered diagnostics to improve precision medicine, and initiatives to contribute further to biopharma partnerships and clinical trials.

Moffitt Cancer Center and PathAI focus on redefining the role of AI and digital pathology in cancer care, setting a brilliant example of how robust technologies and clinical expertise can converge to initiate valuable enhancements in pathology.

Views and Statements from the Company Leaders

MD, Phd, CEO and co-founder of PathAI, Andy Beck, said, “We are excited to collaborate with Moffitt Cancer Center, a renowned institution known for its promising excellence and innovation in cancer care. By bringing AISight Dx and forming a powerful partnership, we’re integrating Moffitt’s pathologists and researchers with the robust tools to contribute to streamlined operations, diagnosis, and uncover important insights from pathology data.”

MD, executive vice president and physician-in-chief at Moffitt Cancer Center, Karen Lu, said, “This partnership fits sincerely with Moffitt’s mission to support the prevention and cure of cancer via transformative care, excellence, innovation, and science. By initiating AISight Dx into our pathology infrastructure, we’re taking a prominent step towards the integration of AI-driven technology into clinical oncology, providing quick and proficient pathologists' review.”

MD, Vice chair of pathology at Moffitt Cancer Center, William Westra, said, “By adopting the digital pathology technologies approach, which also happened to be a major solution to drive Moffitt’s vision for a valuable digital transformation. A transformation that uncovers a wealth of pathology data and enables easy integration with clinical insights and imaging to serve the best of personalized patient care. With the partnership with PathAI, we’re heading towards the building of next-generation oncology research, which will reshape the future of AI-powered care models.”